Source: Annual Congress 2010 - Prognosis of tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. K. Agarwal, K. N. Poddar (Varanasi, Kolkata, India). Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs. Eur Respir J 2010; 36: Suppl. 54, 3103

Member's Comments

No comment yet.

Related content which might interest you: The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis Source: Eur Respir J, 50 (5) 1701552; 10.1183/13993003.01552-2017 Year: 2017 Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy Source: Eur Respir J 2001; 17: 641-646 Year: 2001 Treating multiple-drug resistant tuberculosis Source: International Congress 2018 – PG13 Challenges in the treatment of tuberculosis Year: 2018 Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Treatment outcome of multi-drug resistant tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004 Treatment results in patients with drug resistant pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 612s Year: 2002 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Evaluation of characteristics and treatment results of patients treated as multidrug resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Treatment outcome of multidrug resistant tuberculosis with second line drugs Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001 Resistance of sputum nonspecific microflora in MDR TB patients treated with second-line anti-TB drugs Source: Eur Respir J 2002; 20: Suppl. 38, 614s Year: 2002 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 The efficacy of interferon-alpha in treating multi-drug resistant tuberculosis Source: Annual Congress 2004 - Management of tuberculosis Year: 2004 Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010